Education
About Us
Working with TipRanks
Follow Us
Beta Bionics, Inc. (BBNX)
:BBNX
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.46Last Year’s EPS
―Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: 30.84%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call for Beta Bionics in Q1 2025 reflects a strong performance with significant revenue growth and increased new patient starts, particularly through the pharmacy channel. While there were some challenges, such as a decline in gross margin and increased operating expenses, the company's updated annual guidance and strong cash position indicate a positive outlook.Company Guidance
During the Beta Bionics Q1 2025 earnings call, the company provided updated annual guidance metrics, projecting net sales for the full year to be between $82 million and $87 million, up from the previous guidance of $80 million to $85 million. The company anticipates 22% to 25% of new patient starts to be reimbursed through the pharmacy channel, an increase from the previous target of over 20%. The gross margin for 2025 is now expected to be between 50% and 53%, revised from the prior guidance of at least 50%. In Q1 2025, Beta Bionics reported net sales of $17.6 million, representing a 36% year-over-year growth, with 3,853 new patients adopting the iLet, a 48% increase from the previous year. Approximately 71% of these new patient starts were from individuals previously using multiple daily injections. The company's gross margin for Q1 was 50.9%, down from 55.7% in Q1 2024, primarily due to the increased pharmacy channel adoption, which is expected to drive medium- to long-term gross margin expansion.Strong Revenue Growth
Beta Bionics delivered $17.6 million in net sales for Q1 2025, which represents a 36% year-over-year growth.
Increase in New Patient Starts
The company reported 3,853 new patient starts in Q1 2025, up 48% year-over-year.
Significant Pharmacy Channel Adoption
Low 20s percentage of new patient starts were reimbursed through the pharmacy channel in Q1 2025, surpassing previous guidance and up from mid-single-digit percent in Q1 2024.
Updated 2025 Annual Guidance
Increased projections for 2025: Net sales of $82 million to $87 million, new patient starts through pharmacy channel at 22% to 25%, and gross margin of 50% to 53%.
Strong Cash Position
As of March 31, 2025, Beta Bionics had $295.5 million in cash, cash equivalents, and short- and long-term investments.
BBNX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BBNX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $11.35 | $14.37 | +26.61% |
Mar 25, 2025 | $15.22 | $13.15 | -13.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Beta Bionics, Inc. (BBNX) report earnings?
Beta Bionics, Inc. (BBNX) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Beta Bionics, Inc. (BBNX) earnings time?
Beta Bionics, Inc. (BBNX) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BBNX EPS forecast?
BBNX EPS forecast for the fiscal quarter 2025 (Q2) is -0.46.